Trial Profile
A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma That Contains the Ewing Sarcoma Breakpoint Region 1-activating Transcription Factor-1 (EWSR1-ATF1) Gene Fusion
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs AMG 337 (Primary)
- Indications Clear cell sarcoma
- Focus Therapeutic Use
- Sponsors NantPharma
- 09 Dec 2022 Status changed from active, no longer recruiting to discontinued.
- 03 Nov 2021 Planned End Date changed from 1 Jun 2021 to 1 Dec 2022.
- 03 Nov 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Jun 2022.